Previous 10 | Next 10 |
2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...
2023-06-05 12:50:16 ET Summary Repligen has seen significant growth in the past decade and is well-positioned to benefit from the increasing popularity of biologics. Recent growth has been impacted by unfavorable comparability due to COVID-related revenue, but it is expected to re...
2023-06-05 12:11:00 ET Summary Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With valuations still being demanding, I am fearfu...
2023-05-04 10:23:00 ET Summary Stocks rose on investors’ hopes that moderating inflation and certain weakening economic indicators might lead the Federal Reserve to end its cycle of interest rate increases. The Fund’s investments in the Financials, IT, Industrials, a...
2023-05-02 13:51:06 ET Repligen Corporation (NASDAQ:RGEN) Q1 2023 Earnings Conference Call May 2, 2023, 8:30 AM ET Company Participants Sondra Newman - Head, IR Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Confere...
2023-05-02 07:36:22 ET Repligen press release ( NASDAQ: RGEN ): Q1 Non-GAAP EPS of $0.64 beats by $0.05 . Revenue of $182.66M (-11.5% Y/Y) beats by $1.23M . YEAR 2023 GUIDANCE: Total reported revenue is expected to be in the range of $720-$760 million v...
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in A...
2023-04-25 14:07:06 ET Shares of bioprocessing technology company Repligen (NASDAQ: RGEN) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. That steep decline appears to be connected to the first-quarter earnings report of its fellow bioprocessing and lab specialist, S...
2023-04-20 10:14:49 ET Shares of Life Sciences tool makers Thermo Fisher Scientific ( TMO ), Danaher Corporation ( DHR ), Repligen ( RGEN ), and Bio-Rad Laboratories ( BIO ) came under pressure after their EU peer Sartorius ( OTCPK:SARTF ) disappointed with its Q1 2023 e...
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...